BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 10, 2003
 |  BioCentury  |  Product Development

Actelion: BREATHE to BUILD growth

Actelion Ltd.'s near term growth rests in the hands of its development and marketing teams. With one home-grown and one in-licensed product on the market, the company plans to spend the next few years maximizing sales of Tracleer bosentan and Zavesca miglustat.

Tracleer is marketed to treat pulmonary arterial hypertension (PAH) and Zavesca to treat Gaucher's disease. Where other companies might focus on in-licensing compounds or expediting early stage clinical development programs, ATLN is looking to expand indications for both drugs. If successful, the increased income would enable ATLN to circle back around and build a bigger pipeline.

After booking Tracleer sales of CHF 121.8 million ($90.0 million) in 2002, ATLN lost CHF 40.8 million ($30.2 million) last year. But the fourth quarter loss was only CHF $0.6 million ($0.4 million), and despite increased costs from a bevy of new clinical trials announced last week, CFO Andrew Oakley told the company's analyst day last week that ATLN may turn profitable in 2003 (see "Actelion Pipeline" & B11).

Tracleer has captured about 5% of...

Read the full 867 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >